Regulus Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Regulus Therapeutics has a total shareholder equity of $107.6M and total debt of $540.0K, which brings its debt-to-equity ratio to 0.5%. Its total assets and total liabilities are $114.1M and $6.6M respectively.
Key information
0.5%
Debt to equity ratio
US$540.00k
Debt
Interest coverage ratio | n/a |
Cash | US$97.55m |
Equity | US$107.59m |
Total liabilities | US$6.55m |
Total assets | US$114.14m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 7RG0's short term assets ($101.4M) exceed its short term liabilities ($5.7M).
Long Term Liabilities: 7RG0's short term assets ($101.4M) exceed its long term liabilities ($868.0K).
Debt to Equity History and Analysis
Debt Level: 7RG0 has more cash than its total debt.
Reducing Debt: 7RG0 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 7RG0 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: 7RG0 has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 10.3% each year